drugset / Trial / NCT03510572
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
Phase 0
Completed
20 enrolled
Asan Medical Center
Korea Health Industry Development Institute · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The overall goal of this imaging trial is to evaluate \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).
Timeline
- Start
- 2018-06-04
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | — | Intravenous |